Psych Congress NetworkVortioxetine Improves Depression, Shows Mixed Cognitive Effects in Older Adults

ℹ️ Observational Association Only Evidence

Cognitive impairment is a common and clinically significant feature of late-life depression, contributing to functional decline, reduced independence, and poorer long-term outcomes. Because vortioxetine has been proposed to possess procognitive properties beyond its antidepressant effects, investigators conducted a systematic review of studies published between 2010 and 2025 examining its impact on both depressive symptoms and cognition in adults aged 65 years and older with major depressive disorder. Across 12 randomized and observational studies, antidepressant efficacy was consistently observed, whereas cognitive outcomes varied substantially according to study design, outcome measures, and duration of follow-up.

Clinical Considerations

• Across all included studies, vortioxetine was consistently associated with improvements in depressive symptom severity among older adults with MDD.
• Observational studies generally reported improvements in specific cognitive domains, particularly processing speed, attention, and executive functioning.
• Randomized and comparative studies produced less consistent findings regarding cognition and did not establish clear superiority over placebo or alternative antidepressants for global cognitive outcomes.
• Available evidence suggests any cognitive benefits may be domain-specific rather than reflecting broad improvements across overall cognitive functioning.
• Functional outcomes were evaluated in only five studies, limiting conclusions regarding real-world improvements in independence, daily functioning, or quality of life.
• Some randomized data suggested cognitive improvements diminished over longer follow-up periods, with benefits becoming less apparent by 26 weeks.

Practice Applications

• Consider vortioxetine a reasonable antidepressant option for older adults with MDD when symptom reduction is the primary therapeutic goal.
• Avoid presenting vortioxetine as a proven cognitive-enhancing therapy in late-life depression, as current evidence does not establish a consistent global procognitive effect.
• Recognize that improvements in attention, processing speed, or executive functioning may occur in some patients, but expectations should remain measured.
• Continue evaluating cognitive complaints independently rather than assuming they will improve with antidepressant treatment alone.
• Monitor future longitudinal randomized trials designed to differentiate direct cognitive effects from improvements secondary to depression relief.